National Action Plan for Adverse Drug Event Pre-
vention; and 
(3) require such Committee, in updating the 
National Action Plan for Adverse Drug Event Pre-
vention— 
(A) to consider advances in scientific un-
derstanding and technology pertaining to drug- 
gene-drug interactions, clinical outcomes, health 
care utilization, and the decreasing cost of ge-
netic testing; 
(B) to assess the role of pharmacogenetics 
testing combined with clinical decision support 
as an evidence-based prevention tool; and 
(C) to evaluate operating characteristics 
for Federal adverse drug event surveillance sys-
tems and expand capabilities to identify genetic 
associations in adverse events. 
SEC. 4. ADVERSE DRUG EVENT AND PHARMACOGENOMIC 
TESTING AWARENESS. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 
399V–7. 
ADVERSE 
DRUG 
EVENT 
AND 
PHARMACOGENOMIC TESTING AWARENESS. 
‘‘(a) PUBLIC EDUCATION CAMPAIGN.— 
VerDate Sep 11 2014 
00:31 Mar 05, 2022
Jkt 029200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6875.IH
H6875
kjohnson on DSK79L0C42PROD with BILLS
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Director of the National Human Ge-
nome Research Institute, in consultation with the 
Director of the Eunice Kennedy Shriver National In-
stitute of Child Health and Human Development, 
the Director of the National Center for Bio-
technology Information, and the Director of the Na-
tional Library of Medicine, shall conduct a national 
evidence-based education campaign to increase the 
public’s awareness regarding— 
‘‘(A) the prevalence of adverse drug events 
and adverse drug reactions; 
‘‘(B) specific risk factors that increase an 
individual’s likelihood of experiencing an ad-
verse drug event or adverse drug reaction; 
‘‘(C) 
basic 
information 
about 
pharmacogenomic testing and how its use, in-
cluding incorporation in comprehensive medica-
tion management, may prevent adverse drug re-
actions in certain clinical situations; 
‘‘(D) the role of health care providers in 
performing pharmacogenomic testing, inter-
preting the results of such testing, and adjust-
ing medications based on such results; 
VerDate Sep 11 2014 
00:31 Mar 05, 2022
Jkt 029200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H6875.IH
H6875
kjohnson on DSK79L0C42PROD with BILLS
‘‘(E) the availability of pharmacogenomic 
testing; 
‘‘(F) comprehensive medication manage-
ment; and 
‘‘(G) how the benefits of an individual’s 
pharmacogenomic test results might change or 
be relevant over time. 
‘‘(2) CONSIDERATION
OF
ADVICE
OF
STAKE-
HOLDER EXPERTS.—The education campaign under 
paragraph (1) shall take into consideration the ad-
vice of stakeholder expects, such as those special-
izing in medical genetics and pharmacogenetics and 
collaborative 
communities 
focused 
on 
pharmacogenomics. 
‘‘(3) MEDIA
CAMPAIGN.—In conducting the 
education campaign under paragraph (1), the Sec-
retary, after considering the advice of stakeholder 
experts pursuant to paragraph (2), may award 
grants or contracts to entities to establish national 
multimedia campaigns that may include advertising 
through television, radio, print media, billboards, 
posters, all forms of existing and especially emerging 
social networking media, other Internet media, and 
any other medium determined appropriate by the 
Secretary. 
VerDate Sep 11 2014 
00:31 Mar 05, 2022
Jkt 029200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H6875.IH
H6875
kjohnson on DSK79L0C42PROD with BILLS
‘‘(4) RURAL REGIONS, HEALTH PROFESSIONAL 
SHORTAGE
AREAS, 
AND
UNDERSERVED
COMMU-
NITIES.—The Secretary shall ensure that the edu-
cation campaign under paragraph (1)— 
‘‘(A) reaches rural and medically under-
served communities (as defined in section 799); 
and 
‘‘(B) includes the involvement of commu-
nity health centers, community pharmacies, and 
other local health clinics. 
‘‘(b) HEALTH
CARE
PROFESSIONAL
EDUCATION 
CAMPAIGN.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Director of the National Human Ge-
nome Research Institute, in consultation with the 
Director of the Eunice Kennedy Shriver National In-
stitute of Child Health and Human Development, 
the Director of the National Center for Bio-
technology Information, the Director of the National 
Library of Medicine, and the Administrator of the 
Health Resources and Services Administration, shall 
establish a national health education program for 
health care providers and health care leaders, includ-
ing administrators, pharmacists, nurse practitioners, 
physicians’ assistants, physician medical geneticists, 
VerDate Sep 11 2014 
00:31 Mar 05, 2022
Jkt 029200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H6875.IH
H6875
kjohnson on DSK79L0C42PROD with BILLS